Skip to main content
Sopharma AD logo

Sopharma AD — Investor Relations & Filings

Ticker · SFA ISIN · BG11SOSOBT18 LEI · 097900BGGW0000048796 BSOBGN Manufacturing
Open in API
Filings indexed 1,484 across all filing types
Latest filing 2022-12-02 Director's Dealing
Country BG Bulgaria
Listing BSOBGN SFA

About Sopharma AD

https://www.sopharmagroup.com/

Sopharma AD is a pharmaceutical company founded in 1933 that specializes in the production, distribution, and export of a wide range of medical products. The company's portfolio includes prescription (Rx) and over-the-counter (OTC) medicines, encompassing both branded and generic drugs. A key area of focus is its traditional plant-based products. Sopharma develops treatments for various conditions, including liver disease, pain management, and smoking cessation. Operating from EU-GMP certified facilities, the company also provides contract manufacturing services and has an established presence in over 40 international markets.

Recent filings

Filing Released Lang Actions
Notification from "Telso" AD under Art. 19 of Regulation (EU) No 596/2014 of 1 December 2022.
Director's Dealing Classification · 100% confidence The document is explicitly titled "NOTIFICATION OF INSIDERS' TRANSACTIONS under art. 19 of Regulation 596/2014". It details specific transactions (Sell operations) involving warrants executed by an insider ("Telso" AD related to Vesela Stoeva) in the Company. This directly matches the definition for Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document is a direct report of the transaction, not an announcement of a report's publication.
2022-12-02 English
Notification from "Telso" AD under Art. 19 of Regulation (EU) No 596/2014 of 1 December 2022.
Director's Dealing Classification · 100% confidence The document explicitly states it is a "NOTIFICATION OF INSIDERS' TRANSACTIONS under art. 19 of Regulation 596/2014". It details transactions (Buy operations) executed by an entity related to a director/insider ("Vesela Stoeva") involving the company's shares. This directly corresponds to the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length is short (1454 chars), but it is the report itself, not an announcement of a report, making DIRS the correct classification over RPA or RNS.
2022-12-02 English
Conclusion of transactions from the scope of art. 114, para. 2 of the LPOS
Regulatory Filings Classification · 95% confidence The document is titled "Current report №88/ 2022" and details a specific transaction (a lease agreement annex) concluded by the company, including the parties involved, the value, and the justification for its approval under specific legal articles (Art. 114, para. 2 of the LPOS). This type of disclosure, focusing on related-party transactions or significant corporate actions that require regulatory notification outside of standard periodic reports (like 10-K or IR), fits best under the general category for regulatory announcements that don't match other specific codes. Since it is a formal, dated notification of a specific corporate event/transaction, and it is not an earnings release (ER), management discussion (MDA), or director dealing (DIRS), the most appropriate fallback category is Regulatory Filings (RNS), as it is a mandatory current report. It is not an AGM-R, 10-K, AR, MANG, CT, CAP, DVA, DLST, DIRS, ER, SR, XLSX, FS, CGR, IRAT, IR, IP, LTR, TAR, MRQ, NAV, DIV, PSI, DEF 14A, RPA, SHA, or POS. It is a specific regulatory disclosure.
2022-11-29 English
Consolidated financial report according to IFRS as at 30 September 2022
Regulatory Filings Classification · 19% confidence
2022-11-29 Polish
Tender offer to the shareholders of "Sopharma" AD by "Donev Investments Holding" AD
M&A Activity Classification · 100% confidence The document is a 'NOTIFICATION' from 'Sopharma' AD regarding a 'tender offer' received from a major shareholder, 'DONEV INVESTMENTS HOLDING' AD, for the purchase of shares from remaining shareholders, citing specific articles of the Law on the Public Offering of Securities (LPOS). This document details the offeror's information, the strategic plans post-acquisition, the offer price, and the process for acceptance. This type of mandatory disclosure concerning a takeover bid or tender offer for shares is typically classified under M&A Activity (TAR) or, given the context of a mandatory public offer for shares, it strongly aligns with the scope of takeover/merger activity. It is not an Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or a simple Dividend Notice (DIV). It is a specific announcement related to a change in control/ownership structure via a tender offer, which fits best under M&A Activity (TAR).
2022-11-28 English
Sales revenues for October 2022
Earnings Release Classification · 100% confidence The document is a 'Current report' dated November 7, 2022, providing a brief notification about sales performance (revenue increase) for October 2022 and the ten-month period compared to the previous year. It is very short (501 characters) and functions as a high-level operational update rather than a comprehensive financial statement (like 10-K or IR) or a formal earnings release (ER) which usually contains more detailed figures. Since it is a general regulatory notification providing key operational metrics that doesn't fit the specific categories like DIV, DIRS, or MANG, the most appropriate general category is Regulatory Filings (RNS). Q4 2022
2022-11-07 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.